Department of Medicine, Division of Infectious Diseases, University of Washington, Seattle, Washington, USA.
Department of Neurology, University of Washington, Seattle, Washington, USA.
Clin Infect Dis. 2020 Jul 11;71(2):267-273. doi: 10.1093/cid/ciz795.
Data comparing neurosyphilis treatment regimens are limited.
Participants were enrolled in a study of cerebrospinal fluid (CSF) abnormalities in syphilis that was conducted at the University of Washington between April 2003 to May 2014. They were diagnosed with syphilis and referred by their providers due to concerns for neurosyphilis. We evaluated 150 people with CSF abnormalities who were treated with either intravenous aqueous penicillin G (PenG) or intramuscular aqueous procaine penicillin G plus oral probenecid (APPG-P). An abnormal CSF diagnosis was defined as a white blood cell (WBC) count >20/µL, a CSF protein reading >50 mg/dL, or a reactive CSF-Venereal Disease Research Laboratory test (VDRL). Hazard ratios for normalization of CSF or serum measures were determined using Cox regression.
In individuals treated with either PenG or APPG-P, CSF WBCs and CSF-VDRL reactivity normalized within 12 months after treatment, while protein normalized more slowly and less completely. There was no relationship between treatment regimen or human immunodeficiency virus (HIV) status and likelihood of normalization of any measure. Among those living with HIV, CSF WBC counts and CSF-VDRL reactivity were more likely to normalize in those treated with antiretrovirals. Unexpectedly, CSF WBCs were more likely to normalize in those with low CD4+ T cell counts. When neurosyphilis was more stringently defined as a reactive CSF-VDRL, the relationship with the CD4+ T cell count remained unchanged.
In the current antiretroviral treatment era, neurosyphilis treatment outcomes are not different for PenG and APPG-P, regardless of HIV status. The relationship between the normalization of CSF WBC counts and CD4+ T cell counts may indicate continued imprecision in neurosyphilis diagnostic criteria, due to HIV-related CSF pleocytosis.
比较神经梅毒治疗方案的数据有限。
参与者参加了一项在华盛顿大学进行的关于梅毒脑脊液(CSF)异常的研究,该研究于 2003 年 4 月至 2014 年 5 月进行。他们被诊断患有梅毒,并因担心神经梅毒而由其提供者转介。我们评估了 150 名患有 CSF 异常的患者,他们接受了静脉注射水剂青霉素 G(PenG)或肌内注射水剂普鲁卡因青霉素 G 加口服丙磺舒(APPG-P)治疗。异常 CSF 诊断定义为白细胞(WBC)计数>20/µL、CSF 蛋白读数>50mg/dL 或反应性 CSF-性病研究实验室试验(VDRL)。使用 Cox 回归确定 CSF 或血清指标正常化的风险比。
在接受 PenG 或 APPG-P 治疗的个体中,CSF WBC 和 CSF-VDRL 反应性在治疗后 12 个月内正常化,而蛋白质正常化较慢且不完全。治疗方案或人类免疫缺陷病毒(HIV)状态与任何指标正常化的可能性之间没有关系。在 HIV 感染者中,接受抗逆转录病毒治疗的患者 CSF WBC 计数和 CSF-VDRL 反应性更有可能正常化。出乎意料的是,CD4+T 细胞计数较低的患者 CSF WBC 更有可能正常化。当更严格地将神经梅毒定义为反应性 CSF-VDRL 时,与 CD4+T 细胞计数的关系保持不变。
在当前的抗逆转录病毒治疗时代,无论 HIV 状态如何,PenG 和 APPG-P 的神经梅毒治疗结果没有差异。CSF WBC 计数与 CD4+T 细胞计数正常化之间的关系可能表明,由于 HIV 相关的 CSF 白细胞增多,神经梅毒诊断标准仍存在不准确性。